Literature DB >> 15674323

The CHFR mitotic checkpoint protein delays cell cycle progression by excluding Cyclin B1 from the nucleus.

Matthew K Summers1, John Bothos, Thanos D Halazonetis.   

Abstract

CHFR, a novel checkpoint gene inactivated in human cancer, delays chromosome condensation in cells treated with microtubule poisons. To understand the molecular mechanism for this delay, we characterized cells with inactivated CHFR and stably transfected derivatives expressing the wild-type gene. After exposure to microtubule poisons, the CHFR-expressing cells arrested transiently in early prophase with a characteristic ruffled morphology of the nuclear envelope and no signs of chromosome condensation. Several markers suggested that Cyclin A/Cdc2 had been activated, whereas Aurora-A and -B and Cyclin B1/Cdc2 were inactive. Further, Cyclin B1 was excluded from the nucleus. Ectopic expression of Cyclin B1 with a mutant nuclear export sequence induced chromosome condensation, and thus overcame the CHFR checkpoint. We conclude that the mechanism by which CHFR delays chromosome condensation involves inhibition of accumulation of Cyclin B1 in the nucleus.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15674323     DOI: 10.1038/sj.onc.1208428

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  31 in total

Review 1.  Ubiquitin and SUMO systems in the regulation of mitotic checkpoints.

Authors:  Gustavo J Gutierrez; Ze'ev Ronai
Journal:  Trends Biochem Sci       Date:  2006-05-02       Impact factor: 13.807

2.  Functional interaction between Chfr and Kif22 controls genomic stability.

Authors:  Subbareddy Maddika; Shirley M-H Sy; Junjie Chen
Journal:  J Biol Chem       Date:  2009-03-25       Impact factor: 5.157

Review 3.  Safeguarding entry into mitosis: the antephase checkpoint.

Authors:  Cheen Fei Chin; Foong May Yeong
Journal:  Mol Cell Biol       Date:  2010-01       Impact factor: 4.272

4.  Skp1-Cul1-F-box ubiquitin ligase (SCF(βTrCP))-mediated destruction of the ubiquitin-specific protease USP37 during G2-phase promotes mitotic entry.

Authors:  Amy C Burrows; John Prokop; Matthew K Summers
Journal:  J Biol Chem       Date:  2012-10-01       Impact factor: 5.157

5.  Novel piperazine-based compounds inhibit microtubule dynamics and sensitize colon cancer cells to tumor necrosis factor-induced apoptosis.

Authors:  Avijeet Chopra; Amy Anderson; Charles Giardina
Journal:  J Biol Chem       Date:  2013-12-12       Impact factor: 5.157

6.  CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC.

Authors:  Rathi N Pillai; Seth A Brodie; Gabriel L Sica; You Shaojin; Ge Li; Dana C Nickleach; Liu Yuan; Vijay A Varma; Dacian Bonta; James G Herman; Malcom V Brock; Maria J A Ribeiro; Suresh S Ramalingam; Taofeek K Owonikoko; Fadlo R Khuri; Johann C Brandes
Journal:  Clin Cancer Res       Date:  2013-02-05       Impact factor: 12.531

7.  Involvement of telomerase reverse transcriptase in heterochromatin maintenance.

Authors:  Yoshiko Maida; Mami Yasukawa; Naoko Okamoto; Seii Ohka; Keita Kinoshita; Yasushi Totoki; Takashi K Ito; Tohru Minamino; Hiromi Nakamura; Satoko Yamaguchi; Tatsuhiro Shibata; Kenkichi Masutomi
Journal:  Mol Cell Biol       Date:  2014-02-18       Impact factor: 4.272

8.  Activation of cyclin B1-Cdk1 synchronizes events in the nucleus and the cytoplasm at mitosis.

Authors:  Olivier Gavet; Jonathon Pines
Journal:  J Cell Biol       Date:  2010-04-19       Impact factor: 10.539

9.  Deficiencies in Chfr and Mlh1 synergistically enhance tumor susceptibility in mice.

Authors:  Zheng Fu; Kevin Regan; Lizhi Zhang; Michael H Muders; Stephen N Thibodeau; Amy French; Yanhong Wu; Scott H Kaufmann; Wilma L Lingle; Junjie Chen; Donald J Tindall
Journal:  J Clin Invest       Date:  2009-08-17       Impact factor: 14.808

Review 10.  Physiological and oncogenic Aurora-A pathway.

Authors:  Toshiaki Saeki; Mutsuko Ouchi; Toru Ouchi
Journal:  Int J Biol Sci       Date:  2009-11-26       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.